Product Description
Mebendazole is used to treat infections caused by worms. It works by keeping the worm from absorbing sugar (glucose), so that the worm loses energy and dies. (Sourced from: https://www.mayoclinic.org/drugs-supplements/mebendazole-oral-route/side-effects/drg-20064631?p=1)
Mechanisms of Action: Tubulin Inhibitor,Glucose Uptake Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Hookworm Infections
Known Adverse Events: Abdominal Pain | Pain Unspecified | Stevens-Johnson Syndrome | Agranulocytosis | Neutropenia | Drug Hypersensitivity | Pregnancy Outcomes | Pregnancy, Abdominal | Pregnancy, Prolonged | Anorexia | Diarrhea | Flatulence
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Astrocytoma|Glioblastoma|Gliosarcoma|Optic Nerve Glioma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CCMC1411 | P2 |
Completed |
Gliosarcoma|Optic Nerve Glioma|Glioblastoma|Astrocytoma |
2024-04-01 |